Bile Duct Adenocarcinoma

Diseases /

Back to Diseases List

Overview

NCI Definition: An adenocarcinoma that arises from the intrahepatic bile ducts, the hepatic ducts, or the extrahepatic bile ducts. Adenocarcinomas that arise from the intrahepatic bile ducts or the hepatic ducts are called cholangiocarcinomas. [1]

Clinical Trials

View Clinical Trials for Bile Duct Adenocarcinoma

There are 3 clinical trials for bile duct adenocarcinoma, of which 2 are open and 1 is completed or closed. Of the trials that contain bile duct adenocarcinoma as an inclusion criterion, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).

5b1, pegph20, and atezolizumab are the most common interventions in bile duct adenocarcinoma clinical trials.

Drugs Being Investigated in Bile Duct Adenocarcinoma Trials by Recruiting Status

Significant Genes in Bile Duct Adenocarcinoma

ATM +

ATM is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATR +

ATR is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BARD1 +

BARD1 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRCA1 +

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRCA2 +

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRIP1 +

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 +

CDK12 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CHEK1 +

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CHEK2 +

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCA +

FANCA is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCB +

FANCB is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCC +

FANCC is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCD2 +

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCE +

FANCE is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCF +

FANCF is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCG +

FANCG is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCI +

FANCI is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCL +

FANCL is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCM +

FANCM is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MCPH1 +

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MRE11A +

MRE11A is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NBN +

NBN is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PALB2 +

PALB2 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN +

PTEN is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD50 +

RAD50 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51 +

RAD51 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51B +

RAD51B is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51C +

RAD51C is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51D +

RAD51D is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD54L +

RAD54L is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SLX4 +

SLX4 is an inclusion eligibility criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

Disease Details

Parent(s)

Bile Duct Carcinoma

Children

Cholangiocarcinoma and Bile Duct Mucinous Cystic Neoplasm with an Associated Invasive Carcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.